Browse by Poster Presenter

Skip to main content

ACoP 2024 Main banner

Conference Program

Icon Legend

This session is not in your schedule.

This session is in your schedule. Click again to remove it.

Browse by Poster Presenter

Type here to filter the list

All
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z

C
Cai, Lianjin

University of Pittsburgh
(M-015) Intranasal Diamorphine Population Pharmacokinetics Modeling and Simulation in Pediatric Breakthrough Pain
Lianjin Cai
Favorite
Callisto, Samuel

Metrum Research Group
(W-012) Reinforcement Learning for Pharmacometrics: A Proof of Concept and Future Directions
Samuel Callisto
Favorite
Cao, Youfang

Eisai, Inc
(T-018) A Neuro-Dynamic Quantitative Systems Pharmacology (QSP) Model to Describe Pathophysiology of Alzheimer’s Disease and Inform Drug Development
Youfang Cao
Favorite
Cassani, Simone
(T-019) Simulate modified Nonmem models using NMsim
Simone Cassani
Favorite
Cave, Joseph

Weill Cornell Medical College, Houston Methodist Research Institute
(M-016) Integrating Physiologically Based Pharmacokinetic Modeling with Machine Learning for the Rational Design of Nanoparticles to Improve Safety in Biomedical Applications
Joseph Cave
Favorite
Cha, Hwa Jun

Department of Pharmacology, College of Medicine, the Catholic University of Korea
(T-020) Zolpidemsim: A Web-Application for Simulating Pharmacokinetics of Zolpidem
Hwa Jun Cha
Favorite
Chamzas, Athanasios

University of Maryland School of Pharmacy, Center for Translational Medicine, Baltimore, MD
(W-013) Patent Ductus Arteriosus in Preterm Infants: Exploring Optimal Acetaminophen Dosing for Oral and Rectal Administration
Athanasios Chamzas
Favorite
Chan, Danna

Taiho Oncology, Inc.
(T-021) Semi-physiological population pharmacokinetic (PPK) model using dose optimization data for ASTX030, an oral fixed-dose combination (FDC) of CDA inhibitor cedazuridine and azacitidine in MDS patients
Danna Chan
Favorite
Chang, Yi Chien

University at Buffalo
(T-022) Comparing the Efficacy of Various Insulin Types: A Pharmacokinetic and Pharmacodynamic Modeling Study in Healthy Volunteers
Yi Chien Chang
Favorite
Cheng, ChunFu

University at Buffalo
(T-025) Meta-Analysis of Levamisole Pharmacokinetics Across Diverse Species
ChunFu Cheng
Favorite
Chen, Jingcheng

Drug Clinical Trial Center, Peking University Third Hospital, Beijing 100191, China
(T-060) AI-Driven Innovative Platform in Quantitative Pharmacology: Literature Insights and Automated Model Construction
Jingcheng Chen
Favorite
Chen, Joseph

Genentech
(W-014) Model-Based Meta Analysis for the IPSOS Trial in Platinum Ineligible NSCLC Patients
Joseph Chen
Favorite
Chen, Li

Division of Pharmacotherapy and Experimental Therapeutics, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill
(M-017) A Semi-mechanistic Pharmacokinetic-Pharmacodynamic/Toxicodynamic Model to Guide Dose Optimization of Combination Therapies Targeting DNA Damage Response Pathways
Li Chen
Favorite
Chen, Min

Fudan University
(T-023) Cost-effectiveness of paliperidone palmitate long-acting injectables for the treatment of schizophrenic patients: a joint pharmacometric/pharmacoeconomic approach
Min Chen
Favorite
Chen, Po-Wei

Amgen Inc.
(T-024) A Bayesian Approach to Item Response Theory Modeling for Exposure-Response Relationships in Stan
Po-Wei Chen
Favorite
Chittenden, Jason
(T-026) A Semi-Mechanistic Population Pharmacokinetic (PopPK) Model of Linvoseltamab With Considerations of Disease-Related Factors in Patients (Pts) with Relapsed/refractory (RR) Multiple Myeloma (MM)
Jason Chittenden
Favorite
Choi, Suein

Catholic university of Korea
(T-027) Integrated Microphysiological System and PBPK Modeling for Prediction of Human Diclofenac Pharmacokinetics
Suein Choi
Favorite
Cho, Yu Kyoung

Johnson and Johnson Innovative Medicine
(M-018) Population Pharmacokinetic Assessment of Guselkumab in Adults with Moderately to Severely Active Ulcerative Colitis
Yu Kyoung Cho
Favorite
Clemens, Lara

Simulations Plus, Inc.
(W-015) Eculizumab as a Key Comparator for the Evaluation of Complement Targeted Novel Therapeutic Strategies with a QSP Model
Lara Clemens
Favorite
Cobbina, Enoch

Syndax Pharmceuticals, Inc., Walthman, MA
(W-016) Revumenib physiologically based pharmacokinetic model for evaluation of age effect and CYP3A4-mediated drug-drug interaction in relapsed/refractory acute leukemias
Enoch Cobbina
Favorite
Collins, Kimberly

Critical Path Institute
(M-019) Predictors Of Insulin Dose In Individuals With New-Onset Type 1 Diabetes
Kimberly Collins
Favorite
Combes, francois

Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA
(T-028) Pooled population PK of alpelisib in patients with PIK3CA-related overgrowth spectrum and breast cancer
francois Combes
Favorite
Cortes-Rios, Javiera

University at Buffalo
(W-017) Integrating mathematical modeling with multiplexed immunofluorescence data to predict drug-induced cell arrest
Javiera Cortes-Rios
Favorite
(W-018) Novel computational workflow for selecting virtual patient cohorts for in silico clinical trials
Javiera Cortes-Rios
Favorite
Couty, Claire

Nova In Silico
(M-020) Dissecting Bcl-2 Sensitivity In Acute Myeloid Leukemia: A Quantitative Systems Pharmacology Model For Venetoclax-Azacitidine Therapy
Claire Couty
Favorite
(M-021) Towards A Computational QSP Platform To Support Antibody Drug Conjugate Design In Cancer
Claire Couty
Favorite
(M-022) Towards A QSP Platform To Support Drug Development In Hematological Cancers
Claire Couty
Favorite
Cui, Cheng
(W-129) Frailty phenotype as a sensitive indicator of aging-related Cytochrome P450 3A functional changes：Application of dose optimization recommendations for ticagrelor in the Chinese frail older population
Cheng Cui
Favorite
Cui, Zihan

Critical Path Institute
(T-029) An R-based workflow for clinical trial simulation tool with application in type 1 diabetes studies
Zihan Cui
Favorite